AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02589366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek plus Vital Blue Dye
Description: intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
Study NCT02294305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Study NCT02294305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol 250/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol 250/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol 100/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol 100/50 Dry Powder Inhaler
Description: Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone 100mcg Dry Powder Inhaler
Description: Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Study NCT02061280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone 100mcg Dry Powder Inhaler
Description: Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Study NCT03785262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uroshield
Description: The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
Study NCT03121339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (small)
Description: Tableted oral H1 vaccine (\~140 mg tablet)
Study NCT03121339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-A1.1 H1 Tablet Vaccine (large)
Description: Tableted oral H1 vaccine (\~275 mg tablet)
Study NCT02744001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Diet
Description: 1-week intake of Low Added Sugar Diet 3 day rotating menu
Study NCT04144218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
Study NCT04144218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
Study NCT04250311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-407
Description: MMH-407: For oral use.
Study NCT04250311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: For oral use.
Study NCT03431103 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: 12 week home exercise program
Study NCT04213573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: 38% silver diamine fluoride liquid will be applied with a brush
Study NCT04213573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish
Description: topical fluoride varnish with calcium and phosphate
Study NCT03351985 — intervention group
Intervention type: DEVICE
Intervention: quantitative electroencephalogram (qEEG)
Description: the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
Study NCT03817502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily.
Study NCT03817502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily.
Study NCT04487717 — intervention group
Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study NCT03785262 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Uroshield
Description: The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
Study NCT01664767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur Thermal water
Study NCT01664767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02120677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
Study NCT01090505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: S-1 and oxaliplatin
Description: Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
Study NCT01090505 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Drug: S-1 and oxaliplatin
Description: Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab Prefilled syringe
Description: prefilled syringe
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: capsules
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: tablets
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: solution supplied in vials
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: tablets
Study NCT04585815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-TGT
Description: solution in vials
Study NCT02275416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02275416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 vaccine
Study NCT02275416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study NCT03927768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Predictive Model
Description: Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
Study NCT03927768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Imagers
Description: Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
Study NCT02313896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
Study NCT02092818 — intervention group
Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
Study NCT03944980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel injection
Study NCT03944980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel injection
Study NCT03944980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1-T cells
Description: PD1-T cells injection
Study NCT02451813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apposition of needle bevel against femoral nerve
Description: Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
Study NCT02506621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R test
Study NCT02506621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuubo
Study NCT02708251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate cream
Study NCT02708251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine cream
Study NCT02708251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Study NCT03856320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: An educational video describing obesity treatment options available in the VA.
Study NCT03073850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet
Description: ASA or clopidogrel
Study NCT03073850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oral anticoagulant
Description: Edoxaban of 30mg
Study NCT03073850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose oral anticoagulant
Description: Edoxaban of 60mg
Study NCT02975700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: 1000 mg/day (400 mg in the morning and 600 mg in the evening)
Study NCT02657551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
Study NCT01369654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized decision aid with 1 type of value clarification
Description: Women will be instructed to view a computerized BSO decision support guide.
Study NCT01541202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Study NCT01541202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Study NCT00957385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: 10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
Study NCT02309619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.
Description: Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
Study NCT02467881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Increase (GLB-MOD)
Description: The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.
Study NCT02467881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary Time Decrease (GLB-SED)
Description: As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression.
Study NCT02467881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6-month delayed (DELAYED)
Description: Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
Study NCT01817452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01817452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT01817452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study NCT01817452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Study NCT01817452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT03995511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sagittal Split Osteotomy
Description: Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
Study NCT01624207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic formulation of atorvastatin (Atorva®)
Description: Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
Study NCT01624207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: branded formulation of atorvastatin (Lipitor®)
Description: Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
Study NCT04360655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic microwave intervention
Description: bronchoscopic microwave intervention
Study NCT01969123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124
Study NCT04360655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Description: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Study NCT03462563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEED™
Description: when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
Study NCT03462563 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
Study NCT02819544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride administration
Description: Sodium chloride administration
Study NCT02819544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine administration
Description: Ropivacaine administration
Study NCT01284088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device for adult male circumcision
Description: The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
Study NCT01284088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical circumcision
Description: The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
Study NCT04360655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Description: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Study NCT00782431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell derived, trivalent, seasonal influenza vaccine
Description: Single intramuscular injection
Study NCT02614066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
Study NCT01969123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00782431 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed egg-derived, trivalent seasonal influenza vaccine
Description: Single intramuscular injection
Study NCT01418560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study NCT02155946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Active brain stimulation
Study NCT02155946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Active brain stimulation
Study NCT02155946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Description: Sham (placebo)
Study NCT00762593 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transvaginal placebo device
Description: Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
Study NCT00762593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transvaginal electrical stimulation device
Description: Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
Study NCT02281097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stimulation
Description: Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
Study NCT02281097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation
Description: Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
Study NCT02281097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
Study NCT02281097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
Study NCT00706849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg /mL
Study NCT00706849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mL matching placebo
Study NCT03249688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular health advice
Description: Routine healthy lifestyle counseling
Study NCT03249688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle
Description: Nutritional guidance, exercise, cognitive training, vascular risk monitoring
Study NCT03249688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medical food
Description: Medical food product (Fortasyn Connect)
Study NCT03590431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: extrinsic iodine in milk
Description: 300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.